Introduction

Diabetes medications have transformed the management of type 2 diabetes, enabling millions of patients to achieve glycemic control and reduce microvascular and macrovascular complications. However, a growing body of evidence suggests that certain classes of these drugs exert unintended long-term effects on bone health, including decreased bone mineral density and an elevated risk of fractures. This risk is particularly concerning for older adults, postmenopausal women, and individuals with preexisting osteopenia or osteoporosis. Understanding which medications are implicated, the underlying mechanisms, and how to mitigate these risks is essential for clinicians and patients seeking to balance effective diabetes management with skeletal integrity.

This article provides a comprehensive examination of the relationship between diabetes pharmacotherapy and bone health, with a focus on the most studied agents: thiazolidinediones, sodium-glucose cotransporter 2 inhibitors, and glucagon-like peptide 1 receptor agonists. It also reviews strategies for monitoring bone health in patients with diabetes and discusses alternative treatment approaches that preserve both glycemic control and bone strength.

Diabetes as an Independent Risk Factor for Bone Disease

Before examining medication effects, it is important to recognize that type 2 diabetes itself is associated with increased fracture risk, even after adjusting for bone mineral density. Patients with diabetes tend to have higher bone mineral density than the general population, but paradoxically they experience more fractures. This is partly due to impaired bone quality from accumulation of advanced glycation end-products in collagen, reduced bone turnover, and increased cortical porosity. Additionally, diabetes increases the risk of falls through neuropathy, vision loss, and hypoglycemic events. The interplay between diabetes and bone health creates a complex landscape where medication effects must be evaluated against this baseline risk.

The Spectrum of Diabetes Medications and Their Skeletal Effects

Multiple drug classes are available for managing type 2 diabetes, each with distinct mechanisms of action and side-effect profiles. While most oral hypoglycemic agents are considered safe for bone, several have been associated with adverse skeletal outcomes in observational studies and clinical trials.

Metformin

Metformin remains the first-line therapy for type 2 diabetes due to its efficacy, low cost, and favorable safety profile. Evidence from large cohort studies suggests that metformin has either a neutral or potentially beneficial effect on bone health. Mechanistically, metformin activates AMP-activated protein kinase, which may promote osteoblast differentiation and inhibit osteoclast activity. A meta-analysis of randomized controlled trials found no significant increase in fracture risk among metformin users. Therefore, metformin is generally considered the safest option for patients at high risk of osteoporosis.

Sulfonylureas and Meglitinides

These insulin secretagogues stimulate endogenous insulin release and have been in use for decades. Population-based studies have reported mixed results regarding fracture risk. Some analyses show a modest increase in fracture incidence, possibly due to hypoglycemia and falls rather than direct bone effects. Currently, the evidence does not strongly link sulfonylureas or meglitinides to bone loss, but caution is warranted in frail older adults who are prone to falls.

Thiazolidinediones

Thiazolidinediones, including pioglitazone and rosiglitazone, are peroxisome proliferator-activated receptor gamma (PPAR-γ) agonists. They improve insulin sensitivity by enhancing glucose uptake in adipose tissue, muscle, and liver. However, activation of PPAR-γ in bone marrow mesenchymal stem cells shifts differentiation away from osteoblasts and toward adipocytes, resulting in reduced bone formation. Additionally, thiazolidinediones increase osteoclast activity and promote bone resorption. A landmark Women’s Health Initiative study and subsequent meta-analyses have consistently found a 30-50% increase in fracture risk with thiazolidinedione use, especially in women and older adults. Fractures commonly occur at nonvertebral sites such as the hip, wrist, and foot. The risk appears to be dose-dependent and may persist for years after drug discontinuation.

DPP-4 Inhibitors

Dipeptidyl peptidase-4 (DPP-4) inhibitors, such as sitagliptin and saxagliptin, are generally considered neutral regarding bone health. They raise endogenous GLP-1 levels, which may have favorable effects on bone metabolism. Large cardiovascular outcomes trials and observational studies have not demonstrated an increased fracture risk with DPP-4 inhibitors. However, long-term data are limited, and some studies suggest a possible slight reduction in bone mineral density with prolonged use. For now, they remain a viable option for patients concerned about skeletal effects.

GLP-1 Receptor Agonists

GLP-1 receptor agonists (e.g., liraglutide, semaglutide, exenatide) have gained popularity due to their efficacy in glycemic control and weight loss. Preclinical studies indicate that GLP-1 receptors are expressed on osteoblasts and osteoclasts, and activation may promote bone formation while inhibiting resorption. Clinical trial data are less consistent: some studies show a reduced fracture risk with liraglutide, while others report no significant difference. A recent analysis of the LEADER trial found a lower incidence of fractures in patients treated with liraglutide compared with placebo. However, the weight loss associated with these drugs could theoretically increase fracture risk in older adults by reducing mechanical loading and muscle mass. Overall, GLP-1 agonists are considered safe for bone, with a possible protective effect that may offset any weight loss-related concerns.

SGLT2 Inhibitors

SGLT2 inhibitors (e.g., canagliflozin, dapagliflozin, empagliflozin) are a newer class that reduces blood glucose by promoting urinary glucose excretion. Initial concerns about bone safety emerged from the CANVAS trial, which reported a higher rate of fractures with canagliflozin, particularly in patients with prior fracture or cardiovascular disease. Subsequent studies have yielded conflicting results. The mechanisms hypothesized include volume depletion leading to falls, altered calcium and phosphate homeostasis, and increased parathyroid hormone (PTH) levels. Empagliflozin and dapagliflozin have not shown an elevated fracture risk in major trials. The FDA has issued a warning for canagliflozin regarding increased fracture risk, but the overall evidence is moderate. Patients with preexisting bone disease should be monitored if SGLT2 inhibitors are prescribed.

Insulin

Insulin therapy is often required in advanced diabetes. Hyperinsulinemia can stimulate bone formation via insulin-like growth factor-1 receptors, but the risk of hypoglycemia and falls counterbalances any potential benefit. Large observational studies show either no association or a slight increase in fracture risk among insulin users, likely attributable to underlying disease severity and frailty rather than a direct drug effect. Insulin remains necessary for many patients, but fall prevention strategies are important.

Mechanisms of Bone Loss Induced by Diabetes Medications

The skeletal effects of diabetes drugs arise through multiple interconnected pathways that disturb the delicate balance between bone resorption and formation.

PPAR-γ Activation and Marrow Adiposity

The most well-characterized mechanism is PPAR-γ activation by thiazolidinediones. PPAR-γ is a key regulator of adipogenesis. In the bone marrow microenvironment, PPAR-γ activation diverts mesenchymal stem cells from the osteoblast lineage toward adipose cells. This shift reduces the number and activity of osteoblasts, leading to decreased bone formation. Concurrently, PPAR-γ signaling may enhance osteoclastogenesis by upregulating RANKL expression. The net effect is a negative bone balance and accelerated bone loss, particularly at cortical sites. Histomorphometric studies show increased marrow adipose tissue volume in thiazolidinedione users, which correlates with reduced bone strength.

Osteoblast and Osteoclast Imbalance

Several diabetes drugs alter the expression or activity of osteoblasts and osteoclasts. For SGLT2 inhibitors, the increase in serum phosphate from reduced renal excretion stimulates fibroblast growth factor 23 (FGF23) and PTH. Elevated PTH drives bone resorption, leading to cortical thinning and increased porosity. Additionally, glycosuria-induced volume depletion can activate the renin-angiotensin-aldosterone system, which may have pro-resorptive effects through angiotensin II. In contrast, GLP-1 agonists bind to receptors on osteoblasts, increasing cyclic AMP and promoting osteoblast survival and function. The balance of these effects determines the net skeletal outcome.

Hormonal Changes and Calcium Homeostasis

Diabetes itself is associated with reduced IGF-1 levels and altered sex steroid metabolism, which can impair bone health. Some medications further modulate these hormones. Thiazolidinediones lower circulating estrogen by inhibiting aromatase activity, which may exacerbate bone loss in postmenopausal women. Insulin therapy elevates IGF-1, which theoretically supports bone formation, but the protective effect may be offset by increased sclerostin levels—an inhibitor of bone formation. For SGLT2 inhibitors, the mild metabolic acidosis from ketone production can also stimulate bone resorption by increasing osteoclast activity. Understanding these complex interactions is critical for predicting individual patient risk.

Clinical Implications and Risk Assessment

Given the potential for bone loss, healthcare providers must assess fracture risk when initiating or continuing certain diabetes medications, especially in high-risk populations.

Patient Populations at Higher Risk

  • Postmenopausal women: Already at elevated risk of osteoporosis due to estrogen deficiency, these women are more susceptible to thiazolidinedione-induced bone loss. The combination of PPAR-γ activation and reduced estrogen creates a synergistic negative effect on bone density.
  • Older adults (≥65 years): Age-related declines in bone mineral density, sarcopenia, and higher fall risk amplify the effects of medications that compromise bone strength. Fall risk assessment should be routine.
  • Patients with prior fracture or low bone mineral density: A history of fragility fracture or T-score below -2.5 should prompt careful drug selection and possibly avoidance of thiazolidinediones or canagliflozin.
  • Chronic kidney disease: Renal impairment alters calcium and phosphate metabolism, and SGLT2 inhibitors are contraindicated in advanced CKD (eGFR <30 mL/min). However, thiazolidinediones may accumulate and worsen fluid retention, which can negatively impact bone through reduced mobility.
  • Individuals on glucocorticoids or other bone-depleting agents: Drug interactions may compound skeletal harm. For example, glucocorticoids reduce bone formation and increase resorption, adding to the effects of thiazolidinediones.

Monitoring Bone Health

Baseline dual-energy X-ray absorptiometry is recommended for patients initiating thiazolidinediones or canagliflozin, particularly if they have additional risk factors. Repeat DXA every 1-2 years can track bone mineral density changes. Healthcare providers should also assess renal function, serum calcium, phosphate, and vitamin D levels. Fall risk evaluation and balance training should be incorporated into routine care. For patients on long-term thiazolidinediones, providers should consider switching to a bone-neutral alternative if bone mineral density declines by more than 3-5% yearly. The Fracture Risk Assessment Tool (FRAX) can be used to quantify 10-year fracture probability, though it may underestimate risk in diabetes due to the bone quality issues mentioned earlier.

Managing Diabetes While Protecting Bones

Optimizing diabetes care does not require sacrificing skeletal health. A multifactorial approach that integrates lifestyle measures and thoughtful pharmacotherapy can achieve both goals.

Lifestyle Interventions

Weight-bearing exercise (e.g., walking, jogging, stair-climbing) improves bone density and reduces fall risk. Resistance training two to three times per week strengthens muscles and supports bone formation. Adequate calcium intake (1000-1200 mg/day from diet and supplements) and vitamin D (800-1000 IU/day) are essential, especially for patients on thiazolidinediones or SGLT2 inhibitors. Smoking cessation and moderation of alcohol consumption further protect bone health. A registered dietitian can help design a plan that also supports glycemic targets, including carbohydrate counting and portion control. For patients with diabetes, weight loss is often recommended, but extreme caloric restriction can accelerate bone loss—moderate, sustained weight loss combined with exercise is the safer approach.

Pharmacological Alternatives

When thiazolidinedione therapy is not suitable or bone loss is detected, several alternatives exist:

  • Metformin remains the backbone and is safe for bone. It can be combined with most other agents.
  • GLP-1 receptor agonists offer cardiovascular and weight benefits with possible bone protection. Liraglutide and semaglutide are preferred in patients with osteopenia.
  • DPP-4 inhibitors are neutral and can be used in combination with metformin.
  • SGLT2 inhibitors (except canagliflozin) are generally safe. Empagliflozin or dapagliflozin may be chosen for patients with heart failure or chronic kidney disease.
  • Insulin may be necessary but should be prescribed with fall prevention plans.
  • For patients who require thiazolidinediones (e.g., severe insulin resistance), consider adding a bisphosphonate or denosumab to counteract bone loss, after consulting a bone specialist. A vitamin D and calcium supplement should be prescribed simultaneously if using bisphosphonates.

Shared decision-making is crucial: clinicians should discuss the balance between glycemic benefits and bone risks, incorporating patient preferences and comorbidities. For older adults with high fracture risk, avoiding thiazolidinediones and canagliflozin may be a prudent first step.

Fall Prevention Strategies

Given that many diabetes-related fractures result from falls, fall prevention is a core component of bone health management. This includes reviewing medications that cause orthostatic hypotension or hypoglycemia, optimizing vision and foot care, assessing home safety (e.g., removing trip hazards, improving lighting), and encouraging balance exercises such as tai chi or yoga. For patients on insulin or sulfonylureas, reducing hypoglycemia risk through careful dose adjustment and continuous glucose monitoring can decrease fall-related fractures.

Future Directions in Research

Ongoing studies aim to clarify the skeletal safety of newer diabetes agents and identify biomarkers that predict bone loss. High-resolution peripheral quantitative computed tomography is being used to assess bone microarchitecture changes beyond bone mineral density, providing a more comprehensive picture of drug effects on bone quality. Research into PPAR-γ modulators with reduced bone effects (so-called selective PPAR-γ modulators) may yield safer thiazolidinedione analogues that retain insulin-sensitizing properties without adverse skeletal consequences. Additionally, the role of the gut microbiome in regulating bone metabolism through incretin hormones like GLP-1 is an emerging frontier. Large, prospective trials with fracture as a primary endpoint are needed to establish causality and guide clinical decisions with greater precision.

Conclusion

Certain diabetes medications, particularly thiazolidinediones and possibly canagliflozin, pose long-term risks to bone health that warrant attention. The mechanisms involve PPAR-γ activation, altered calcium homeostasis, and hormonal shifts, leading to decreased bone density and increased fracture incidence. In contrast, metformin, GLP-1 agonists, and most DPP-4 inhibitors are safe for bone. Managing diabetes in patients at risk of osteoporosis requires a proactive approach: baseline dual-energy X-ray absorptiometry, regular monitoring, lifestyle optimization, and selection of bone-neutral or bone-protective drugs. As the diabetes pharmacopeia expands, clinicians must integrate skeletal safety into personalized treatment plans. Ongoing research will refine our understanding and hopefully yield medications that control glucose without compromising the skeleton.

For further reading, see the American Diabetes Association’s Standards of Care (diabetes.org), the UK Prospective Diabetes Study (UKPDS 33), the CANVAS trial analysis (Neal et al., 2017), and a recent review on diabetes and bone health (Lecka-Czernik & Rosen, 2020).